WIC
CPRX

Whitegate Investment Counselors’s Catalyst Pharmaceutical CPRX Stock Holding History

Whitegate Investment Counselors’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-10,000
Closed -$53K – 203
2019
Q3 		$53K Hold
10,000
– – 0.01% 192
2019
Q2 		$38K Hold
10,000
– – 0.01% 195
2019
Q1 		$51K Hold
10,000
– – 0.01% 193
2018
Q4 		$19K Buy
+10,000
New +$28.6K ﹤0.01% 192

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Prudential Financial
Prudential Financial Newark, New Jersey $81.2B AUM 27.81% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return

Whitegate Investment Counselors's CPRX Position: Q4 2019 in Review

Whitegate Investment Counselors sold out of Catalyst Pharmaceutical (CPRX) in Q4 2019, closing a stake of 10,000 shares — an estimated $53K sold.

Whitegate Investment Counselors first reported a position in CPRX in Q4 2018 and held it in 4 quarters. The position peaked at $53K in Q3 2019. 130 funds tracked by Wall St. Rank hold CPRX as of Q4 2019.

  • Whitegate Investment Counselors reported no remaining Catalyst Pharmaceutical position as of Q4 2019 after selling out during the quarter.
  • Whitegate Investment Counselors sold 10,000 Catalyst Pharmaceutical shares in Q4 2019, an estimated $53K.
  • Whitegate Investment Counselors first reported a position in Catalyst Pharmaceutical in Q4 2018 and held it in 4 quarters.
  • Whitegate Investment Counselors's Catalyst Pharmaceutical position peaked at $53K in Q3 2019.
  • 130 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q4 2019.

Based on Whitegate Investment Counselors's 13F filing for Q4 2019, filed 14 Jan 2020.